Clinical DevelopmentLast reviewed May 2026

Investigator's Brochure(IB)

A comprehensive document summarizing clinical and nonclinical data on an investigational product for clinical trial investigators.

Usage Examples

The IB was updated with Phase 2 efficacy data prior to Phase 3 trial initiation.
A new safety signal from the ongoing DSUR triggered an IB supplementary update and protocol amendment.
Investigators reviewed the IB during site initiation training.

What is IB?

The Investigator's Brochure (IB) is a compilation of the known clinical and nonclinical information on an investigational medicinal product that is relevant to its study in human subjects. The IB provides clinical investigators and other trial personnel with the information needed to understand the rationale for the protocol and to comply with its key design features, dose regimens, and safety monitoring procedures.

ICH E6 and E8 require an IB for every clinical trial of an investigational product. The IB must include physical/chemical/pharmaceutical properties, nonclinical pharmacology and toxicology summaries, clinical effects and safety, marketing experience (if any), and guidance for the investigator on risk management. The IB is updated at least annually and whenever significant new information emerges (safety signals, new indication data, PK updates).

IB updates are regulatory events: sponsors must distribute the new version to investigators and IRBs, and significant safety updates often require concurrent protocol amendments and informed consent updates. The IB is referenced in every IND, CTA, and DSUR; inconsistencies between the IB and other submission documents are a common source of regulatory questions.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E6, ICH E8, 21 CFR 312.

FDAEMAPMDA

When This Matters

The IB was updated with Phase 2 efficacy data prior to Phase 3 trial initiation.
A new safety signal from the ongoing DSUR triggered an IB supplementary update and protocol amendment.
Investigators reviewed the IB during site initiation training.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E6ICH E821 CFR 312

Frequently Asked Questions

At minimum annually per ICH E6 and E8. Sponsors must also update the IB whenever significant new information emerges that affects the risk-benefit assessment — new serious adverse events, dose-limiting toxicities, contraindications, or material changes in efficacy or safety profile.

Primarily clinical trial investigators and site staff, to understand the product's profile and protocol rationale. IRBs/Ethics Committees review the IB as part of trial approval. Regulatory authorities (FDA, EMA, others) reference the IB in IND/CTA review and DSUR review. Monitors and sponsors use it to guide safety assessments.

The IB itself is not separately approved. It is submitted as part of the IND (US) or CTA (EU and other regions) and is updated throughout the trial. Significant updates may trigger IRB and regulatory review of the trial as a whole. FDA reviews the IB during IND-enabling review and again during safety reviews.